Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vivitrol for Cannabis Dependence
NCT02088177Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Oct 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of naltrexone in cannabis use disorder (CUD), sponsored by New York State Psychiatric Institute. Primary endpoints: Change in Marijuana Use at 8 weeks and Number of Participants Receiving the Second Injection at 5 weeks. Started Oct 2014; status: completed.
02
Drugs
naltrexone
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT02088177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02088177.